Potek bolezni pri bolnicah s HER-2 pozitivnim rakom dojk
Breast cancer is the most frequent cancer in women. The course and efficiency of breast cancer treatment are influenced by several factors. The expression of HER-2 protein and HER-2 gene is gaining in strength in breast cancer management. The aim of our study was to compare the course of HER-2 positive with HER-2 negative disease. In median time of 2.5 years DFS (disease-free-survival) of patients with HER-2 positive tumours was 76.1%, and 93.4% for patients with HER-2 negative disease. HER-2 status was the strongest prognostic factor for DFS (p
by Authors
2008
2018-08-31 13:32:45
1060
Domen
Ribnikar
70
Špela
Fink
70
Snježana
Frković-Grazio
70
Hotimir
Lešničar
70
Aleksander
Sadikov
70
Tanja
Čufer
70
UDK
4
616-006
ISSN pri članku
9
1408-1741
URN
14
URN:NBN:SI:doc-JJWIMRX6
COBISS_ID
3
25343193
OceCobissID
13
65324032
RAZ_Ribnikar_Domen_i2008.pdf
236206
Predstavitvena datoteka
2018-08-31 13:32:45